BioSpace News Archive

The advanced wound care market is predicted to display steadfast growth over the forecast period from 2020 to 2030.

The increasing cases of infectious diseases are a prime factor augmenting the growth of the global digital PCR and real-time PCR market during the forecast period set between 2020 and2030.

The drive for monitoring antimicrobial resistance in agricultural settings by public health policy makers in various countries is a key trend in the expansion of the veterinary antimicrobial susceptibility testing market.

Recursion Pharmaceuticals, Inc. announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share.

Oncopeptides AB, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, announces that the Company has submitted an application to the European Medicines Agency, EMA, for conditional marketing authorization of melflufen in the EU, based on the pivotal phase 2 HORIZON study in relapsed refractory multiple myeloma.

Synlogic a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $3.00 per share.

Tauriga Sciences, Inc., a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums, additional product offerings, as well as an ongoing Pharmaceutical Development initiative, showcased the blister pack design for its newest, proprietary, Tauri-Gum™ SKU.

Eli Lilly and Company has requested the U.S. Food and Drug Administration revoke the Emergency Use Authorization for bamlanivimab 700 mg alone.

Bausch Health Companies Inc., Bausch + Lomb, its leading global eye health business, and Nicox, an international ophthalmology company, announced that VYZULTA®, 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency.

Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with virally triggered or maintained immune responses, announced an interview with Chairman and CEO, Greg Duncan, will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, April 17, 2021 at 7 p.m.